Search clinical trials for: CLS001 (Omiganan)

Total 246 results

Maruho Co., Ltd.

Completed

Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle

Rosacea

United States, France, United Kingdom, Germany, Australia, Canada, New Zealand, Netherlands, Sweden
Maruho Co., Ltd.

Completed

Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle

Rosacea

United States, France, United Kingdom, Germany, Canada, Netherlands, New Zealand, Australia, Sweden
Maruho Co., Ltd.
Leiden University Medical Center

Completed

Pharmacodynamics, Safety and Efficacy of Topical Omiganan in Patients With External Genital Warts

Condylomata Acuminata (External)

Netherlands
Maruho Co., Ltd.

Completed

Pharmacodynamics, Safety/Tolerability and Efficacy of Topical Omiganan in Patients With uVIN

Usual Type Vulval Intraepithelial Neoplasia (uVIN)

Netherlands
Maruho Co., Ltd.

Completed

A Study to Evaluate the Safety and Efficacy of Omiganan (CLS001) Topical Gel Versus Vehicle in Female Subjects With Moderate to Severe Acne Vulgaris

Acne Vulgaris

United States
Maruho Co., Ltd.

Completed

Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel

Rosacea

United States, United Kingdom, Canada, New Zealand, Australia, France, Sweden, Netherlands
Maruho Co., Ltd.

Completed

A Twelve Week Safety and Efficacy Study in Rosacea

Papulopustular Rosacea

United States
Maruho Co., Ltd.

Completed

Topical Challenge With Omiganan and Imiquimod in Healthy Volunteers

Healthy

Netherlands
Maruho Co., Ltd.

Completed

Pharmacodynamics of Omiganan (CLS001) in Patients With Atopic Dermatitis

Atopic Dermatitis

Netherlands
Maruho Co., Ltd.

Completed

A 21 Day Pharmacokinetics Study in Papulopustular Rosacea

Papulopustular Rosacea

United States
Maruho Co., Ltd.

Completed

Safety and Efficacy Study of CLS001Topical Gel Compared to Vehicle in Subjects With Inflammatory Acne Vulgaris

Acne Vulgaris

United States
BioWest Therapeutics Inc

Completed

Safety and Efficacy of MBI 226 2.5% and 5.0% Topical Acne Solutions in the Treatment of Acne

Acne Vulgaris | Acne | Propionibacterium Acnes
BioWest Therapeutics Inc

Completed

Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections

Sepsis | Fungemia | Bacteremia

United States
Maruho Co., Ltd.

Completed

Pharmacodynamics of Omiganan BID in Patients With Atopic Dermatitis

Atopic Dermatitis

Netherlands
Maruho Co., Ltd.

Completed

A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts

Cutaneous Common Warts

United States
Maruho Co., Ltd.

Completed

First-in-Human Study of CLS003 ICVT in Subjects With Cutaneous Warts

Cutaneous Warts

Netherlands
BioWest Therapeutics Inc

Completed

Safety and Efficacy of MBI 226 1.25% and 2.5% Topical Acne Solutions in the Treatment of Acne

Acne Vulgaris | Acne | Propionibacterium Acnes
Capella Bioscience Ltd
Centessa Pharmaceuticals plc

Terminated

Study of Intravenously Administered Anti-LIGHT Monoclonal Antibody CBS001 in Healthy Volunteers

Chronic Inflammatory Disease

United Kingdom
Cadence Pharmaceuticals

Completed

Study of Antimicrobial Activity of Omiganan 1% Gel vs. Chlorhexidine 2% for Topical Skin Antisepsis in Healthy Adult Subjects

Infection

United States
Lisata Therapeutics, Inc.

Completed

CLBS201 in Patients With Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)

Chronic Kidney Diseases

United States
Chiesi Farmaceutici S.p.A.

Completed

PK of CHF6001 in Subjects With Mild, Moderate and Severe Renal Impairment vs. Healthy Volunteers

Chronic Obstructive Pulmonary Disease

Bulgaria
University Hospital, Gentofte, Copenhagen
Sanofi

Completed

Effect of Bile Acid Secretion and Sequestration on GLP-1 Secretion

Diabetes Mellitus, Type 2

Denmark
ImStem Biotechnology
Rho, Inc.

Recruiting

A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis

Multiple Sclerosis

United States
QIAGEN Gaithersburg, Inc

Completed

Evaluation of the QuantiFERON-TB Test.

Tuberculosis

United States
Cadence Pharmaceuticals

Completed

Study of Omiganan 1% Gel in Preventing Catheter Infections/Colonization in Patients With Central Venous Catheters

Infection

United States, Germany, France, Spain
Integro Theranostics

Recruiting

LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer

Breast Cancer | DCIS | Invasive Duct Carcinoma of Breast

United States
Vesper Biotechnologies ApS

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001 in Healthy Participants (SORT-IN-1)

Dementia, Frontotemporal

Netherlands
Alector Inc.

Active, not recruiting

A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

Frontotemporal Dementia

Spain, United States, Portugal, United Kingdom, France, Germany, Netherlands, Belgium, Australia, Italy, Turkey, Switzerland, Argentina, Canada, Greece, Sweden
QIAGEN Gaithersburg, Inc

Completed

Evaluation of the 4th Generation QuantiFERON-TB Test (QFT-Plus) for the Detection of Tuberculosis Infection

Tuberculosis

United States
QIAGEN Gaithersburg, Inc

Completed

Evaluation of the QuantiFERON-TB Test.

Tuberculosis

United States
Maruho Co., Ltd.

Terminated

ICVT in HPV-induced Genital Lesions of Immunocompromised and Immunocompetent Patients

HPV-Induced Genital Lesions

Netherlands
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
CStone Pharmaceuticals

Recruiting

A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Alexandra Marine and General Hospital

Unknown

A STUDY TO EVALUATE THE EFFICACY OF CJH1 (CLR4001) IN PARKINSON'S DISEASE

Parkinson's Disease

Canada
CStone Pharmaceuticals

Completed

Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients

Relapsed Small Cell Lung Cancer

China
CStone Pharmaceuticals

Completed

A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma

Hodgkin Lymphoma

China
Fudan University

Unknown

Toripalimab in the Neoadjuvant Treatment of BRAF V600 Wild Type Melanoma (FU-Name-T001)

Melanoma Stage IIIB-IV

China
Anbiome Labs LLC
Sarajevo School of Science and Technology, Medical School Department; Public...

Completed

RCT to Evaluate the Cosmetic Efficacy of Demo-cosmetic Active Ingredient CLS02021

Dry Skin; Eczema | Overall Skin Appearance

Bosnia and Herzegovina
Zhejiang University

Not yet recruiting

Safety and Efficacy Clinical Study of Severe Hemophilia B Treatment With KL001

Hemophilia B Without Inhibitor
Calibr, a division of Scripps Research

Enrolling by invitation

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

Transformed Follicular Lymphoma | Burkitt Lymphoma | Waldenstrom Macroglobulinemia | Lymphoplasmacytic Lymphoma | Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Primary Mediastinal Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma (DLBCL) | Mantle Cell Lymphoma (MCL) | Follicular... and other conditions

United States
CStone Pharmaceuticals

Recruiting

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

Advanced Solid Tumor | Advanced Lymphoma

China, Australia, United States
Vertex Pharmaceuticals Incorporated
CRISPR Therapeutics

Enrolling by invitation

A Long-term Follow-up Study in Participants Who Received CTX001

Hematologic Diseases | Genetic Diseases, Inborn | Sickle Cell Disease | Hemoglobinopathies | Sickle Cell Anemia | Thalassemia | Beta-Thalassemia

United States, Canada, Italy, United Kingdom, Germany
CStone Pharmaceuticals

Completed

A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors

Advanced Cancer

China
CStone Pharmaceuticals
Bayer

Completed

A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors

Advanced Refractory Solid Tumors

Australia
Fudan University

Active, not recruiting

PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) Patients

Triple Negative Breast Cancer

China
Xinqiao Hospital of Chongqing
Chongqing University Cancer Hospital; Southwest Hospital, China; Daping Hospital...

Recruiting

Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC

Treatment-naive Advanced Non-small Cell Lung Cancer

China
Alector Inc.

Active, not recruiting

A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)

Frontotemporal Dementia

Canada, United States, Germany, United Kingdom, Italy, Netherlands
RenJi Hospital

Not yet recruiting

A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Efficacy of HCL001 Cell Injection (Homologous Allogeneic Hepatocytes) in Patients With Decompensated Cirrhosis

Decompensated Cirrhosis
Radboud University Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development; Brain... and other collaborators

Recruiting

Promoting Resilience in Youth Through Mindfulness mEditation (PRYME)

Internalizing Problems

Netherlands
Johnson & Johnson Surgical Vision, Inc.

Active, not recruiting

Proof-of-concept Study for a New Intraocular Lens, MODEL C0001

Cataract

France

Search clinical trials for: CLS001 (Omiganan)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations